Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Lesner

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Current Pharmaceutical Design|September 29, 2012
Future of protease activity assaysMagdalena Wysocka, Adam Lesner
Expert Opinion on Therapeutic Patents|October 2, 2013
Inhibitors of cathepsin G: a patent review (2005 to present)Paulina Kosikowska, Adam Lesner
Expert Opinion on Therapeutic Patents|April 12, 2016
Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003-2015)Paulina Kosikowska, Adam Lesner
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|May 9, 2022
Chemical tools to monitor bladder cancer progressionNatalia Gruba, Lech Stachurski, Adam Lesner
Chemistry & Biodiversity|January 26, 2021
Non-Proteasomal Urine Activity in Bladder CancerNatalia Gruba, Lech Stachurski, Adam Lesner
Journal of Biochemistry|June 24, 2021
Elastolytic activity is associated with inflammation in bladder cancerNatalia Gruba, Lech Stachurski, Adam Lesner
Bioorganic Chemistry|February 21, 2023
Novel tools to study West Nile virus NS3 protease activityJoanna Pianka, Natalia Gruba, Adam Lesner
Bioorganic Chemistry|September 4, 2023
Initial study of the detection of ADAM 10 in the urine of type-2 diabetic patientsNatalia Gruba, Agnieszka Piwkowska, Adam Lesner
Bioorganic Chemistry|April 3, 2026
Utility of FRET substrates in bladder cancer diagnosisNatalia Gruba, Lech Stachurski, Adam Lesner
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|October 27, 2021
Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancerNatalia Gruba, Patrycja Rachubik, Agnieszka Piwkowska, et al.
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Current Pharmaceutical Design|September 29, 2012
Future of protease activity assaysMagdalena Wysocka, Adam Lesner
Expert Opinion on Therapeutic Patents|October 2, 2013
Inhibitors of cathepsin G: a patent review (2005 to present)Paulina Kosikowska, Adam Lesner
Expert Opinion on Therapeutic Patents|April 12, 2016
Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003-2015)Paulina Kosikowska, Adam Lesner
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|May 9, 2022
Chemical tools to monitor bladder cancer progressionNatalia Gruba, Lech Stachurski, Adam Lesner
Chemistry & Biodiversity|January 26, 2021
Non-Proteasomal Urine Activity in Bladder CancerNatalia Gruba, Lech Stachurski, Adam Lesner
Journal of Biochemistry|June 24, 2021
Elastolytic activity is associated with inflammation in bladder cancerNatalia Gruba, Lech Stachurski, Adam Lesner
Bioorganic Chemistry|February 21, 2023
Novel tools to study West Nile virus NS3 protease activityJoanna Pianka, Natalia Gruba, Adam Lesner
Bioorganic Chemistry|September 4, 2023
Initial study of the detection of ADAM 10 in the urine of type-2 diabetic patientsNatalia Gruba, Agnieszka Piwkowska, Adam Lesner
Bioorganic Chemistry|April 3, 2026
Utility of FRET substrates in bladder cancer diagnosisNatalia Gruba, Lech Stachurski, Adam Lesner
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|October 27, 2021
Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancerNatalia Gruba, Patrycja Rachubik, Agnieszka Piwkowska, et al.
Pageof 12